You are here

"Recovering plasma" as a treatment for COVID-19

Author: Bolysbek Dana 

Translator: Tursunova Balkadisha 

Editor: Akhmetova Aigerim    



A New study was conducted by scientists from Argentina. It compared the results of 228 hospitalized COVID-19 patients who received an infusion of so-called "convalescent plasma" with the results of 105 patients who did not receive an infusion (the"placebo group"). All the patients were seriously ill. 


As a result, after one month, there were no significant differences between the two groups in terms of clinical outcomes. In both groups, about 11% of people died. 


The theory behind the use of blood plasma from people who have been ill and are fighting COVID-19 is that the plasma contains immune system agents that can help recipients in their fight against the disease. 


But a previous study conducted in India-this time involving patients with "moderate" COVID-19-also found little benefit from treatment in preventing the disease from progressing to a more severe stage. This study, conducted by Dr. Anup Agarwal of the Indian Council of medical research in new Delhi, was published on October 22 in the BMJ. 


"There have been several major trials that have shown the same results: the plasma of convalescents does not seem to affect the course of COVID-19," said Dr. Mangala Narasimhan. She is senior Vice President and Director of intensive care services at Northwell Health, new Hyde Park, new York. 


Narasimhan also noted that in the Argentine trial, even with a good measurement of the amount of antibodies they gave people in blood transfusions, there was no benefit. She believes that other treatments should remain first-line options for severe COVID-19.